Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(17/week)
India
(8/week)
Singapore
(2/week)
China, P. R.
(1/week)
Philippines
(1/week)
View all
(31/week)
News
United States
(1121/week)
Manufacturing
(562/week)
Technology
(1133/week)
Energy
(412/week)
Other Manufacturing
(384/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Protein kinase inhibitors
Oct 22, 2019
BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib
Oct 03, 2019
MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies
Oct 02, 2019
BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting
Sep 29, 2019
Novartis Kisqali® delivers consistently superior overall survival - MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
Sep 29, 2019
Verzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study
Sep 27, 2019
BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib at the European Society for Medical Oncology (ESMO) 2019 Congress
Sep 19, 2019
Addition of KISQALI® to drug plan in Quebec expands access to treatment for metastatic breast cancer
Sep 17, 2019
Mylan Expands Oncology Portfolio with Launch of Generic Faslodex® Injection, a Treatment for Advanced Breast Cancer
Sep 10, 2019
HR Positive/ HER2 Negative Breast Cancer Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Sep 03, 2019
Rho kinase inhibitor, "Ripasudil Hydrochloride Hydrate" IND application for Phase 2 clinical study in the United States Indication for Corneal Endothelial Diseases [Developmental code: K-321]
Aug 19, 2019
BerGenBio ASA: Results for the Second Quarter and First Half 2019
Jul 30, 2019
Lilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Jun 14, 2019
BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy
Jun 14, 2019
Tolero Pharmaceuticals Presents Clinical Data from Ongoing Phase 1 Zella 101 Study Evaluating Investigational Agent Alvocidib in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed AML at EHA 2019
Jun 01, 2019
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
May 24, 2019
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
May 21, 2019
The anaplastic lymphoma kinase (ALK) inhibitors market will register a CAGR of about 21% by 2023
May 20, 2019
Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology
May 16, 2019
Tolero Pharmaceuticals to Highlight Clinical Data Evaluating Investigational Agent Alvocidib in Patients with Newly Diagnosed AML at EHA 2019
May 15, 2019
BerGenBio to Present New NSCLC and AML Clinical Data and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019
‹‹
Page 2
››
Latest News
Sep 1, 2024
Insta Max 20K Puffs Vape: The Future of Vaping Has Arrived
Sep 1, 2024
Kodiak Gas Services Announces 2023 Schedule K-3 Investor Tax Packages for CSI Compressco LP Are Available...
Aug 31, 2024
Suzano completes purchase of 15% stake in Lenzing AG
Aug 31, 2024
Noble Corporation plc announces changes to its share capital including share repurchases for the month of...
Aug 31, 2024
FP Markets Wins Double at FMPS 2024
Aug 31, 2024
Kenya airport workers' union delays strike again
Aug 31, 2024
CGTN: China, Africa set to embrace closer economic, trade ties at FOCAC
Aug 31, 2024
United Imaging Healthcare Reports nearly 30% YoY Growth in Overseas Market Revenue, H1 Revenue Reaches 5.33...
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
View All Events